PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for NVO (Novo Nordisk A/S) from 1990 to Aug 13 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Novo Nordisk A/S stock (NVO) PE ratio as of Aug 13 2020 is 24.21. More Details

Novo Nordisk A/S PE Ratio (TTM) Chart

EMBED

Novo Nordisk A/S PE Ratio (TTM) Historical Data

Total 1269
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Novo Nordisk A/S PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-08-1325.6 2020-06-1125.4
2020-08-1225.7 2020-06-1026.2
2020-08-1124.9 2020-06-0925.5
2020-08-1024.7 2020-06-0825.3
2020-08-0724.7 2020-06-0525.4
2020-08-0624.4 2020-06-0425.3
2020-08-0524.9 2020-06-0325.5
2020-08-0424.7 2020-06-0225.7
2020-08-0325.0 2020-06-0125.9
2020-07-3125.0 2020-05-2926.0
2020-07-3025.7 2020-05-2825.6
2020-07-2925.6 2020-05-2724.7
2020-07-2825.7 2020-05-2625.0
2020-07-2725.8 2020-05-2525.5
2020-07-2425.3 2020-05-2225.5
2020-07-2325.4 2020-05-2125.5
2020-07-2226.2 2020-05-2025.6
2020-07-2126.1 2020-05-1925.4
2020-07-2026.2 2020-05-1825.1
2020-07-1725.7 2020-05-1525.2
2020-07-1625.1 2020-05-1425.3
2020-07-1525.5 2020-05-1324.9
2020-07-1425.1 2020-05-1224.6
2020-07-1324.9 2020-05-1125.2
2020-07-1025.0 2020-05-0824.7
2020-07-0925.1 2020-05-0724.5
2020-07-0825.2 2020-05-0624.4
2020-07-0724.9 2020-05-0524.9
2020-07-0625.2 2020-05-0425.1
2020-07-0325.4 2020-05-0125.0
2020-07-0225.4 2020-04-3024.9
2020-07-0125.1 2020-04-2924.8
2020-06-3025.1 2020-04-2825.4
2020-06-2925.1 2020-04-2725.7
2020-06-2626.0 2020-04-2425.6
2020-06-2526.5 2020-04-2325.2
2020-06-2426.2 2020-04-2225.4
2020-06-2326.8 2020-04-2125.3
2020-06-2226.8 2020-04-2025.3
2020-06-1926.6 2020-04-1724.8
2020-06-1826.0 2020-04-1624.3
2020-06-1726.3 2020-04-1523.6
2020-06-1625.7 2020-04-1423.6
2020-06-1525.8 2020-04-1323.2
2020-06-1225.5 2020-04-1023.6

Novo Nordisk A/S PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2836
Address Novo Alle 1, Bagsvaerd, DNK, DK-2880
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.